Extracellular matrix protection factor 1 (ECPF-1), a novel osteoarthritis therapeutic demonstrates chondroprotective properties in a rat model of osteoarthritis; a microcomputed tomography and histological analysis

Amy Bhatt; Brian Heist; Joseph Musiol; Jamil Shariff; Jazmine Loman; Paige Black; Frederick J Lombard; Ellen Cho; Sarah Chmielewski; Tiffany C Holmes; Belinda Beqo; Jeremiah Kinsey; Patrisia Mattioli; Lyudamila Lukashova; Abdulhafez A Selim; Marina D'Angelo

Extracellular matrix protection factor 1 (ECPF-1), a novel osteoarthritis therapeutic demonstrates chondroprotective properties in a rat model of osteoarthritis; a microcomputed tomography and histological analysis

Amy Bhatt, Brian Heist, Joseph Musiol, Jamil Shariff, Jazmine Loman, Paige Black, Frederick J Lombard, Ellen Cho, Sarah Chmielewski, Tiffany C Holmes, Belinda Beqo, Jeremiah Kinsey, Patrisia Mattioli, Lyudamila Lukashova, Abdulhafez A Selim, Marina D'Angelo

Department of Bio-Medical Sciences (PCOM)

Research output: Contribution to conference › Presentation

Abstract

Introduction: Osteoarthritis (OA) is a common degenerative joint disease of multifactorial etiology causing pain and disability in more than 25% of the adult population. Despite affecting a vast amount of the population, there is currently no therapy available that successfully suspends or reverses the deterioration of cartilage and bone occurring in OA.

Objectives: Current pharmacological treatment of OA targets inflammation and pain management through non-steroidal anti-inflammatory drugs, intra-articular corticosteroids, and analgesics. Extracellular Matrix Protection Factor 1 (ECPF-1) is a novel therapeutic that inhibits specific matrix metalloproteinases (MMPs) that are involved in degradation of the extracellular matrix (ECM) in cartilage during OA.

Methods: In this study, a chemically-induced rat model of OA in the knee joint was utilized to investigate the effects of ECPF-1 at various concentrations in early stage osteoarthritis. The progression of post-traumatic OA in this study was assessed using microcomputed tomography (µCT) and histological analysis via Hematoxylin and Eosin, Safranin-O, and Periodic acid–Schiff staining. The acute effects of OA progression were studied on a timeline of 4 and 8 weeks.

Results: The µCT data showed that at both the 4-week post-loading (4 weekly injections of ECPF-1) and 8-week protection-extension phases, the ECPF-1 treated cohort demonstrated decreased ECM degradation compared to untreated controls. Improved articular cartilage histological staining of the ECPF-1 treated joints supported the µCT image data for the femur and tibia.

Discussion: These results show that ECPF-1 could be utilized in chondroprotection against alteration of ECM metabolism involved in OA. This study shows a potential for ECPF-1 as a possible therapeutic for slowing the progression of OA in an acute setting.

Original language	American English
State	Published - May 10 2021

Keywords

Safranin stain
microcomputed tomography
osteoarthritis treatment

Disciplines

Life Sciences
Medicine and Health Sciences

Cite this

Bhatt, A., Heist, B., Musiol, J., Shariff, J., Loman, J., Black, P., Lombard, F. J., Cho, E., Chmielewski, S., Holmes, T. C., Beqo, B., Kinsey, J., Mattioli, P., Lukashova, L., Selim, A. A., & D'Angelo, M. (2021). Extracellular matrix protection factor 1 (ECPF-1), a novel osteoarthritis therapeutic demonstrates chondroprotective properties in a rat model of osteoarthritis; a microcomputed tomography and histological analysis.

Bhatt, A, Heist, B, Musiol, J, Shariff, J, Loman, J, Black, P, Lombard, FJ, Cho, E, Chmielewski, S, Holmes, TC, Beqo, B, Kinsey, J, Mattioli, P, Lukashova, L, Selim, AA & D'Angelo, M 2021, 'Extracellular matrix protection factor 1 (ECPF-1), a novel osteoarthritis therapeutic demonstrates chondroprotective properties in a rat model of osteoarthritis; a microcomputed tomography and histological analysis'.

@conference{0571ab716f5c459aaadaba4de6edaf74,

title = "Extracellular matrix protection factor 1 (ECPF-1), a novel osteoarthritis therapeutic demonstrates chondroprotective properties in a rat model of osteoarthritis; a microcomputed tomography and histological analysis",

abstract = " Introduction: Osteoarthritis (OA) is a common degenerative joint disease of multifactorial etiology causing pain and disability in more than 25% of the adult population. Despite affecting a vast amount of the population, there is currently no therapy available that successfully suspends or reverses the deterioration of cartilage and bone occurring in OA. Objectives: Current pharmacological treatment of OA targets inflammation and pain management through non-steroidal anti-inflammatory drugs, intra-articular corticosteroids, and analgesics. Extracellular Matrix Protection Factor 1 (ECPF-1) is a novel therapeutic that inhibits specific matrix metalloproteinases (MMPs) that are involved in degradation of the extracellular matrix (ECM) in cartilage during OA. Methods: In this study, a chemically-induced rat model of OA in the knee joint was utilized to investigate the effects of ECPF-1 at various concentrations in early stage osteoarthritis. The progression of post-traumatic OA in this study was assessed using microcomputed tomography (µCT) and histological analysis via Hematoxylin and Eosin, Safranin-O, and Periodic acid–Schiff staining. The acute effects of OA progression were studied on a timeline of 4 and 8 weeks. Results: The µCT data showed that at both the 4-week post-loading (4 weekly injections of ECPF-1) and 8-week protection-extension phases, the ECPF-1 treated cohort demonstrated decreased ECM degradation compared to untreated controls. Improved articular cartilage histological staining of the ECPF-1 treated joints supported the µCT image data for the femur and tibia. Discussion: These results show that ECPF-1 could be utilized in chondroprotection against alteration of ECM metabolism involved in OA. This study shows a potential for ECPF-1 as a possible therapeutic for slowing the progression of OA in an acute setting.",

keywords = "Safranin stain, microcomputed tomography, osteoarthritis treatment",

author = "Amy Bhatt and Brian Heist and Joseph Musiol and Jamil Shariff and Jazmine Loman and Paige Black and Lombard, {Frederick J} and Ellen Cho and Sarah Chmielewski and Holmes, {Tiffany C} and Belinda Beqo and Jeremiah Kinsey and Patrisia Mattioli and Lyudamila Lukashova and Selim, {Abdulhafez A} and Marina D'Angelo",

year = "2021",

month = may,

day = "10",

language = "American English",

}

TY - CONF

T1 - Extracellular matrix protection factor 1 (ECPF-1), a novel osteoarthritis therapeutic demonstrates chondroprotective properties in a rat model of osteoarthritis; a microcomputed tomography and histological analysis

AU - Bhatt, Amy

AU - Heist, Brian

AU - Musiol, Joseph

AU - Shariff, Jamil

AU - Loman, Jazmine

AU - Black, Paige

AU - Lombard, Frederick J

AU - Cho, Ellen

AU - Chmielewski, Sarah

AU - Holmes, Tiffany C

AU - Beqo, Belinda

AU - Kinsey, Jeremiah

AU - Mattioli, Patrisia

AU - Lukashova, Lyudamila

AU - Selim, Abdulhafez A

AU - D'Angelo, Marina

PY - 2021/5/10

Y1 - 2021/5/10

N2 - Introduction: Osteoarthritis (OA) is a common degenerative joint disease of multifactorial etiology causing pain and disability in more than 25% of the adult population. Despite affecting a vast amount of the population, there is currently no therapy available that successfully suspends or reverses the deterioration of cartilage and bone occurring in OA. Objectives: Current pharmacological treatment of OA targets inflammation and pain management through non-steroidal anti-inflammatory drugs, intra-articular corticosteroids, and analgesics. Extracellular Matrix Protection Factor 1 (ECPF-1) is a novel therapeutic that inhibits specific matrix metalloproteinases (MMPs) that are involved in degradation of the extracellular matrix (ECM) in cartilage during OA. Methods: In this study, a chemically-induced rat model of OA in the knee joint was utilized to investigate the effects of ECPF-1 at various concentrations in early stage osteoarthritis. The progression of post-traumatic OA in this study was assessed using microcomputed tomography (µCT) and histological analysis via Hematoxylin and Eosin, Safranin-O, and Periodic acid–Schiff staining. The acute effects of OA progression were studied on a timeline of 4 and 8 weeks. Results: The µCT data showed that at both the 4-week post-loading (4 weekly injections of ECPF-1) and 8-week protection-extension phases, the ECPF-1 treated cohort demonstrated decreased ECM degradation compared to untreated controls. Improved articular cartilage histological staining of the ECPF-1 treated joints supported the µCT image data for the femur and tibia. Discussion: These results show that ECPF-1 could be utilized in chondroprotection against alteration of ECM metabolism involved in OA. This study shows a potential for ECPF-1 as a possible therapeutic for slowing the progression of OA in an acute setting.

AB - Introduction: Osteoarthritis (OA) is a common degenerative joint disease of multifactorial etiology causing pain and disability in more than 25% of the adult population. Despite affecting a vast amount of the population, there is currently no therapy available that successfully suspends or reverses the deterioration of cartilage and bone occurring in OA. Objectives: Current pharmacological treatment of OA targets inflammation and pain management through non-steroidal anti-inflammatory drugs, intra-articular corticosteroids, and analgesics. Extracellular Matrix Protection Factor 1 (ECPF-1) is a novel therapeutic that inhibits specific matrix metalloproteinases (MMPs) that are involved in degradation of the extracellular matrix (ECM) in cartilage during OA. Methods: In this study, a chemically-induced rat model of OA in the knee joint was utilized to investigate the effects of ECPF-1 at various concentrations in early stage osteoarthritis. The progression of post-traumatic OA in this study was assessed using microcomputed tomography (µCT) and histological analysis via Hematoxylin and Eosin, Safranin-O, and Periodic acid–Schiff staining. The acute effects of OA progression were studied on a timeline of 4 and 8 weeks. Results: The µCT data showed that at both the 4-week post-loading (4 weekly injections of ECPF-1) and 8-week protection-extension phases, the ECPF-1 treated cohort demonstrated decreased ECM degradation compared to untreated controls. Improved articular cartilage histological staining of the ECPF-1 treated joints supported the µCT image data for the femur and tibia. Discussion: These results show that ECPF-1 could be utilized in chondroprotection against alteration of ECM metabolism involved in OA. This study shows a potential for ECPF-1 as a possible therapeutic for slowing the progression of OA in an acute setting.

KW - Safranin stain

KW - microcomputed tomography

KW - osteoarthritis treatment

UR - https://digitalcommons.pcom.edu/research_day/research_week_2021/research2021/32

M3 - Presentation

ER -

Extracellular matrix protection factor 1 (ECPF-1), a novel osteoarthritis therapeutic demonstrates chondroprotective properties in a rat model of osteoarthritis; a microcomputed tomography and histological analysis

Abstract

Keywords

Disciplines

Other files and links

Cite this